Table 6 Pathway enrichment analysis of primary targets
NO | KEGG signaling pathway | Count | P value |
|---|---|---|---|
1 | Hepatitis B | 13 | 8.33×10–8 |
2 | Pathways in cancer | 18 | 4.15×10–8 |
3 | Colorectal cancer | 8 | 7.40×10–7 |
4 | cGMP-PKG signaling pathway | 11 | 7.41×10–7 |
5 | Apoptosis | 8 | 9.57×10–7 |
6 | HIF-1 signaling pathway | 9 | 3.80×10–6 |
7 | Small cell lung cancer | 8 | 1.12×10–5 |
8 | Prostate cancer | 8 | 2.21×10–5 |
9 | p53 signaling pathway | 7 | 4.57×10–5 |
10 | cAMP signaling pathway | 10 | 7.88×10–5 |
11 | Amyotrophic lateral sclerosis | 6 | 8.25×10–5 |
12 | Salivary secretion | 7 | 9.76×10–5 |
13 | Regulation of lipolysis in adipocytes | 6 | 1.79×10–4 |
14 | Tuberculosis | 9 | 2.79×10–4 |
15 | Osteoclast differentiation | 8 | 2.81×10–4 |
16 | Calcium signaling pathway | 9 | 4.01×10–4 |
17 | Estrogen signaling pathway | 7 | 4.23×10–4 |
18 | HTLV-I infection | 10 | 5.57×10–4 |
19 | Proteoglycans in cancer | 9 | 6.07×10–4 |
20 | TNF signaling pathway | 7 | 7.01×10–4 |